178 related articles for article (PubMed ID: 11065150)
21. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
Niekel MC; Bipat S; Stoker J
Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer.
Briggs RH; Chowdhury FU; Lodge JP; Scarsbrook AF
Clin Radiol; 2011 Dec; 66(12):1167-74. PubMed ID: 21867996
[TBL] [Abstract][Full Text] [Related]
24. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
26. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
[TBL] [Abstract][Full Text] [Related]
27. Controversies in the management of colorectal liver metastases: role of PET and PET/CT.
Wiering B; Vogel WV; Ruers TJ; Oyen WJ
Dig Surg; 2008; 25(6):413-20. PubMed ID: 19212113
[TBL] [Abstract][Full Text] [Related]
28. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
29. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Contrast-Enhanced CT and [
Wagner F; Hakami YA; Warnock G; Fischer G; Huellner MW; Veit-Haibach P
Mol Imaging Biol; 2017 Oct; 19(5):795-803. PubMed ID: 28224325
[TBL] [Abstract][Full Text] [Related]
31. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
[TBL] [Abstract][Full Text] [Related]
32. Colorectal cancer patients before resection of hepatic metastases. Impact of (18)F-FDG PET on detecting extrahepatic disease.
Rosa F; Meimarakis G; Stahl A; Bumm R; Hahn K; Tatsch K; Dresel S
Nuklearmedizin; 2004 Aug; 43(4):135-40. PubMed ID: 15316581
[TBL] [Abstract][Full Text] [Related]
33. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
Wiering B; Ruers TJ; Oyen WJ
Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
[TBL] [Abstract][Full Text] [Related]
34. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
[TBL] [Abstract][Full Text] [Related]
35. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).
Fernandez FG; Drebin JA; Linehan DC; Dehdashti F; Siegel BA; Strasberg SM
Ann Surg; 2004 Sep; 240(3):438-47; discussion 447-50. PubMed ID: 15319715
[TBL] [Abstract][Full Text] [Related]
36. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery.
Wiering B; Ruers TJ; Krabbe PF; Dekker HM; Oyen WJ
Ann Surg Oncol; 2007 Feb; 14(2):818-26. PubMed ID: 17136470
[TBL] [Abstract][Full Text] [Related]
37. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
[TBL] [Abstract][Full Text] [Related]
38. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
[TBL] [Abstract][Full Text] [Related]
39. The role of FDG-PET in the selection of patients with colorectal liver metastases.
Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
[TBL] [Abstract][Full Text] [Related]
40. [Imaging in the diagnosis of colorectal liver metastases and extrahepatic abnormalities].
Bipat S; van Leeuwen MS; Oyen WJ; Planting AS; IJzermans JN; Stoker J
Ned Tijdschr Geneeskd; 2008 Apr; 152(15):857-62. PubMed ID: 18512524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
